News

US-based pharmaceutical company Azaya Therapeutics has announced that it has been selected by the National Cancer Institute for a research collaboration to study Azaya’s lead cancer therapy, ATI-1123.

INT131-007 is a 24 week, high dose active comparator (45mg Actos) and placebo controlled study of INT131 at four doses in poorly controlled type 2 diabetics. According to

Through this validation study, AMDL and Mayo Clinic will perform clinical diagnostic testing to compare AMDL’s DR-70 (FDP) cancer test with a newly developed, next generation test. The

Mount Sinai School of Medicine has been added as a center for the Phase II study because of its reputation in dermatological research. It is anticipated that the

Switzerland-based Basilea Pharmaceutica has announced that the Scottish Medicines Consortium has accepted Toctino for use within National Health Service Scotland for the treatment of adults with severe chronic

Mr Hanson is a founding partner of Barnard Life Sciences, a healthcare consulting company founded in 2001. From 2004 to 2009, Mr Hanson was a member of the

Tolerx, a biopharmaceutical company, has announced that Defend, the Phase III trial of otelixizumab, an investigational novel targeted immunotherapeutic, has started enrollment of new onset autoimmune type 1

BioImagene has said that its iScan slide scanners address the challenges posed by traditional microscopy by providing a powerful, highly automated and collaborative platform that supports the entire

Azzalure has received the UK approval for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown, in adult men and women